Japan AIDS Patents, Mar 15-31

[Alan Engel]

The Japanese AIDS-related patent applications listed below were published 
March 15-31, 1995.  A list of applications published January 1 - March 31, 1995 
can be found at http://www.netaxs.com/~aengel/JapanAIDSPatents/list.htm

JP95-72059A, 95-3-17, Method to detect biochemical substances and 
biochemical substance detecting sensor using said method
Sogo Pharmaceuticals (Japan) (591222566)
Method to precisely, quantitatively, and simply detect DNA hybrids 
and sensor using said method.

JP95-72060A, 95-3-17, Method to detect biochemical substances and 
biochemical substance detecting sensor using said method
Sogo Pharmaceuticals (Japan) (591222566)
Method to precisely, quantitatively, and simply detect DNA hybrids 
and sensor using said method.

JP95-72144A, 95-3-17, Method for disrupting red blood cells
Immunotek (France) (591069237)
Method analyzes white blood cells by disrupting red blood cells 
while preserving white blood cells.

JP95-76525A, 95-3-20, Method for stabilizing interleukin-1ß complex
Otsuka Pharmaceutical (Japan) (000206956)
Method for stabilizing interleukin-1ß complex containing 
interleukin-1ß (IL-1ß) and human serum albumin

JP95-79780A, 95-3-28, Method for making recombinant ADF
Ajinomoto Ltd. (Japan) (000000066)
Method for making recombinant ADF by culturing Bacillus coli which 
has been transformed by a plasmid containing the gene for human ADF

JP95-80062A, 95-3-28, Apparatus for removing endotoxins and method 
for making purified blood
Asahi Medical (Japan) (000116806)
Apparatus which removes white blood cells such as monocytes and 
granulocyts from blood and thereby indirectly removes endotoxins 
and cytokines due to endotoxins

JP95-82300A, 95-3-28, Antitumor substance
Green Cross (Japan) (000137764) / Polar Kasei (000113470)
Antitumor agent which is conjugated to A7 chimera antibody and 
neocarzinostatin

JP95-79795A, 95-3-28, Method for making cell line which produces 
human monoclonal antibodies
Takeda Pharmaceuticals (Japan) (000002934)
Human lymphocytes are implanted into SCID mice and the obtained 
sensitized lymphocytes made into a line for producing human 
monoclonal antibodies.